Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1-mutant Glioma”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)WithdrawnNCT04737174
What this trial is testing

ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors

Who this might be right for
Epilepsy; Seizure
ES Therapeutics Australia Pty Ltd
Early research (Phase 1)Looking for participantsNCT05609994
What this trial is testing

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Who this might be right for
Low Grade Glioma of Brain
Katy Peters, MD, PhD 48
Testing effectiveness (Phase 2)Looking for participantsNCT06161974
What this trial is testing

Study of Olutasidenib and Temozolomide in HGG

Who this might be right for
High Grade GliomaAstrocytomaAstrocytoma, Grade III+16 more
Rigel Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT04056910
What this trial is testing

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Who this might be right for
Advanced Solid TumorIDH1 MutationGlioma
Jason J. Luke, MD 15
Early research (Phase 1)Active Not RecruitingNCT05484622
What this trial is testing

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Who this might be right for
AstrocytomaOligodendroglioma
Institut de Recherches Internationales Servier 60
Very early researchActive Not RecruitingNCT05076513
What this trial is testing

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

Who this might be right for
GlioblastomaGlioblastoma MultiformeGlioma+3 more
Nader Sanai 42
Early research (Phase 1)Not Yet RecruitingNCT07629089
What this trial is testing

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

Who this might be right for
Brain Cancer
Megan Mantica 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Not applicableNot Yet RecruitingNCT06969352
What this trial is testing

A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

Who this might be right for
Gliomas
Servier (Tianjin) Pharmaceutical Co. LTD. 60
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Not applicableWithdrawnNCT06648473
What this trial is testing

Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

Who this might be right for
Low Grade Glioma of Brain
Duke University
Not applicableLooking for participantsNCT07608003
What this trial is testing

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

Who this might be right for
Gliomas Harboring IDH1 and/or IDH2 MutationsGlioma Glioblastoma MultiformeGlioma of Brainstem+3 more
Xiangya Hospital of Central South University 500
Testing effectiveness (Phase 2)WithdrawnNCT02977689
What this trial is testing

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Who this might be right for
Glioma
NYU Langone Health
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Early research (Phase 1)Study completedNCT03343197
What this trial is testing

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Who this might be right for
Glioma
Institut de Recherches Internationales Servier 49
Large-scale testing (Phase 3)Looking for participantsNCT05303519
What this trial is testing

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Who this might be right for
GliomaAstrocytoma, Grade IVIDH1-mutant Glioma+5 more
Nuvation Bio Inc. 365
Testing effectiveness (Phase 2)Active Not RecruitingNCT04458272
What this trial is testing

DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Who this might be right for
WHO Grade II Glioma
Daiichi Sankyo Co., Ltd. 25
Not applicableNot Yet RecruitingNCT07219199
What this trial is testing

Residual IDH1-Mutant Tumor Cell Quantification Study

Who this might be right for
Glioma
NYU Langone Health 105